Explore every episode of the podcast The Longevity Podcast: Alzheimer's and Brain Health Research

Send us Fan Mail

Can flickering light and sound at 40 beats per second, delivered through a virtual reality headset, safely engage the brain in early Alzheimer's disease? In this small single-session feasibility study, 11 older adults with mild cognitive impairment due to Alzheimer's or mild Alzheimer's dementia explored three immersive VR environments with 40 Hz audiovisual stimulation and a sham comparison while their brain waves were recorded by EEG. Everyone finished the session with no serious side effects, the 40 Hz stimulation produced clearly stronger brain responses at that frequency than sham, and in early exploratory tests video-word pairs learned during 40 Hz stimulation were remembered better than those learned during sham. We talk about what this early study can and can't tell us, and what longer at-home studies would need to show.

Source: Reis C, Hainke L, Headley G, Navarro S, Zanto TP, Certain R. "Feasibility of immersive 40 Hz gamma sensory stimulation in early-stage Alzheimer's disease." The Journal of Prevention of Alzheimer's Disease, 2026;13(10):100679. DOI: https://doi.org/10.1016/j.tjpad.2026.100679. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/).

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

How common is dementia among older Americans, and who carries the heaviest burden? This study used the 2023 National Health and Aging Trends Study, a nationally representative sample of 7,574 older adults, to estimate probable and possible dementia and the factors tied to it. Older age, less education, stroke, falls, and depression or anxiety went with higher odds, while vision correction and hearing aid use went with lower odds. The gaps were striking: Hispanic adults 85 and older had about a 60% predicted probability of probable dementia versus about 35% for non-Hispanic White adults, and chewing or swallowing problems mattered far more for Hispanic adults. We talk about what the study can and can't show, and why hearing, dental, and mental health care may matter for brain health.

Source: Lee YS, Cruz JA, Kabakibi M, Moore A, Lee JA, Jun HJ. "Prevalence, risk factors, and racial disparities in probable and possible dementia: the national health and aging trends study." The Journal of Prevention of Alzheimer's Disease, 2026;13(10):100676. DOI: https://doi.org/10.1016/j.tjpad.2026.100676. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/).

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Can your heart-risk score hint at how fast your memory and thinking may change? In this editorial, Dr. Maileen Ulep looks at a rural U.S. study (Project FRONTIER) that used the American Heart Association's PREVENT equations to estimate 10-year cardiovascular risk. Each 10-point rise in that risk went with about one extra point of yearly decline on a standard memory and thinking test, especially in attention and delayed memory. We talk about why rural communities are understudied, what the study can and can't show, and why checking heart risk early in life may be one of the best ways to protect brain health.

Source: Ulep MG. "What's good for the heart is good for the brain? Evidence from a rural cohort on the longitudinal relationship between atherosclerotic cardiovascular disease risk and cognitive decline." The Journal of Prevention of Alzheimer's Disease, 2026;13(9):100672. DOI: https://doi.org/10.1016/j.tjpad.2026.100672. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/).

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

New disease-modifying therapies are changing Alzheimer's care, but the trials behind them rarely measured frailty, the loss of physical reserve that is common in older adults with Alzheimer's. In this review, a group of European geriatricians and neurologists explains what frailty is and how it's measured, why it may affect safety and benefit, and the open questions and ethical grey zones. They propose a frailty-informed, step-by-step pathway, starting with simple screening in primary care, to guide more individualized decisions. Frailty, they stress, is not a simple yes-or-no for treatment. This episode is for education only, not medical advice.

Source: Bellelli G, Brignoli O, Canevelli M, et al. "Integrating frailty into decision-making for disease-modifying therapies in Alzheimer's disease: a proposed expert-opinion based approach." The Journal of Prevention of Alzheimer's Disease, 2026;13(9):100666. DOI: https://doi.org/10.1016/j.tjpad.2026.100666. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/).

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Did omega-3 supplement use really go along with faster memory decline in older adults? After two letters challenged their ADNI-based study, study authors Liao and Wang reply point by point: how supplement use was measured, which confounders were and weren't covered, why their result differs from earlier work on the same data, and what their brain-scan findings can and can't show. Their bottom line: the link is a signal worth checking, not proof of harm and not a reason to stop supplements or change guidelines. We walk through the back-and-forth and what it teaches about reading nutrition and brain-health research.

Source: Liao ZB, Wang YR. "Response to two letters on omega-3 supplementation and cognitive decline." The Journal of Prevention of Alzheimer's Disease, 2026;13(9):100662. DOI: https://doi.org/10.1016/j.tjpad.2026.100662. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/).

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Did omega-3 supplements really speed up memory decline in older adults? A recent study using the ADNI cohort suggested they might, contradicting earlier work on the same data that linked omega-3 use to lower Alzheimer's risk. In this letter to the editor, researchers Simon Dyall and Mélanie Plourde dig into why: large amounts of missing data, limited adjustment for key dementia risk factors, and other methodological issues that can make results look very different. We unpack what this debate teaches about reading nutrition and brain-health research.

Source: Dyall SC, Plourde M. "Do methodological limitations and confounding factors explain the apparent acceleration of cognitive decline in older adults taking omega-3 fatty acid supplements?" The Journal of Prevention of Alzheimer's Disease, 2026;13(9):100661. DOI: https://doi.org/10.1016/j.tjpad.2026.100661. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/).

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

What do people in their 40s, 50s, and early 60s with mild cognitive impairment actually do to protect their brain health, and what gets in the way? This scoping review from University College Dublin screened 6,349 records and mapped 17 studies from Asia, Europe, North America, and Africa. Strategies fell into two groups: structured programs such as aerobic exercise, dance, cognitive training, mindfulness, and multi-part lifestyle programs, and everyday self-directed habits such as diet, memory tricks, and mentally stimulating hobbies. We look at what helped people stick with these strategies, what held them back, and the equity gaps the authors found, including few participants from rural or lower-income settings, fewer men, and limited ethnic diversity. Their message: brain health programs should be designed with midlife adults, not just for them.

Source: Dookhy J, McCague Y, Hickson J, Stokes D, Kroll T, Frazer K, Brain health strategies in middle-aged individuals with mild neurocognitive disorder: a scoping review, J Prev Alzheimers Dis 2026;13(9):100657. https://doi.org/10.1016/j.tjpad.2026.100657 (CC BY 4.0)

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

How often does dementia show up in older adults who live at home but need advanced care such as tube feeding, breathing support, catheters, stoma or enema care, wound or pain care, or dialysis? A nationwide survey in Taiwan visited 11,297 community-dwelling older adults between 2020 and 2022. About 6.5% received at least one kind of advanced care, and in that group dementia was more than twice as common (18.0% vs 8.0%). The highest odds were seen with stoma or enema care, tube feeding, dialysis, urinary catheters, and respiratory care. Among people with dementia, day-night confusion and resistance to care were notably more common when advanced care was involved. We talk through what this cross-sectional study can and cannot show, and the authors' message for clinicians and care partners: look for undiagnosed dementia in people with complex care needs, and use patient-centered, non-drug approaches to ease symptoms and caregiver strain.

Source: Jhang KM, Tung YC, Wang WF, Chung HJ, Liao HY, Huang LC, Hsu CC, Yang YH, Prevalence of dementia and BPSD in community-dwelling older adults with advanced care needs: a nationwide survey in Taiwan, J Prev Alzheimers Dis 2026;13(9):100656. https://doi.org/10.1016/j.tjpad.2026.100656 (CC BY 4.0)

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

New anti-amyloid antibody treatments for early Alzheimer's are now authorized in Europe, but how many patients in a real memory clinic actually qualify? A team in Modena, Italy, applied the Italian appropriate use recommendations step by step to all 1,080 patients seen at their cognitive neurology clinic in 2024 and 2025. Of those, 596 had mild cognitive impairment or mild Alzheimer's dementia, 230 had biomarker-confirmed Alzheimer's, and 50 ended up treatment-ready. That is 4.6% of the clinic, 8.4% of people with a mild clinical diagnosis, and 21.7% of those with confirmed biomarkers. The biggest hurdles were having moved past the mild stage, MRI findings or being unable to have MRI, and care-context needs such as caregiver support for repeated infusions and monitoring. The authors argue that planning should always state which group a percentage refers to, that eligibility screening should start early, and that not qualifying should never mean a withdrawal of care.

Source: Zamboni G, Tondelli M, Vinceti G, Gallingani C, Bercini Z, Barbieri A, Carbone C, Iacovino N, Cossutti S, Ballotta D, Salemme S, Chiari A, From regulatory approval to clinical practice: real-world eligibility for anti-amyloid monoclonal antibodies in an Italian dementia-care network, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100655 (CC BY 4.0)

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Can the conditions of everyday life, like money, stress, schooling, neighborhood, and access to care, leave a mark on the brain by age 40? Using the CARDIA study, researchers built a 12-item social determinants of health index across five domains and followed 3,488 adults from early midlife, 645 of them with repeated brain MRI. People in the most disadvantaged group already scored lower on thinking tests at the start. Over each five-year stretch they also showed faster decline in processing speed, faster build-up of white matter hyperintensities (small signs of blood-vessel damage), and faster loss of gray matter volume than the least disadvantaged group. The findings are associations, not proof of cause, and the cohort included only Black and White adults from four U.S. cities. The authors suggest that easing social disadvantage by midlife or earlier may help protect brain health.

Source: Dintica CS, Cheunkarndee J, Bryan RN, Launer LJ, Yaffe K, Comprehensive social determinants of health and brain health in midlife, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100652 (CC BY 4.0)

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Can loneliness, depression, and stress make your body age faster on the inside? Researchers pooled 22 studies of adults from midlife onward that measured "epigenetic age," a biological age estimated from DNA methylation patterns in blood. Greater loneliness, depression, and psychosocial stress were each linked to faster epigenetic aging, most consistently on newer clocks such as PhenoAge and GrimAge that track health and lifespan. The links were modest, and they show association rather than cause. The authors point out that no eligible studies looked at anxiety, that all included studies came from Western countries, and that trials are needed to see whether easing these burdens can slow biological aging.

Source: Guo J, Shan J, Ye KX, Liang W, Wang Y, Ang ET, Lee TS, Suckling J, Maier AB, Feng L, Psychological adversities and epigenetic ageing in midlife and older age: A systematic review and meta-analysis, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100650 (CC BY 4.0)

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

At what age does measurable thinking decline actually begin? Researchers pooled long-term data on 14,389 adults aged 22 to 94 from three population studies in China, the United States, and the Czech Republic, putting different cognitive tests on a common 0 to 100 scale and following people for an average of seven to nine years. A small but detectable drop in overall cognition first showed up in the 31 to 40 age group and grew steadily larger with age. Non-memory skills such as attention and executive function showed change from about age 31, while significant memory decline appeared only after 50. Individual paths varied widely, so age alone did not predict who would decline. The authors say the findings support looking at midlife cognitive monitoring and a life-course approach to brain health, while noting the limits of combining different tests across cohorts.

Source: Novotný JS, Klil-Drori S, Geda YE, Nasreddine Z, Stokin GB, Timing of cognitive decline onset and life-course trajectories: A pooled longitudinal analysis of 14,389 adults across three cohorts, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100649 (CC BY 4.0)

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

The choroid plexus is the tissue inside the brain's ventricles that makes cerebrospinal fluid and helps clear waste. Earlier imaging studies found it grows larger across the Alzheimer's continuum, but few had checked that against autopsy, the gold standard for diagnosis. Toronto researchers used National Alzheimer's Coordinating Center data on 111 people who had a brain MRI within five years of death and a post-mortem exam. A larger choroid plexus, adjusted for head size, went along with intermediate and high levels of Alzheimer's pathology and with cognitive impairment, while women had smaller volumes than men. Among people with similar high pathology, those with more impairment tended to have larger volumes. The authors say longitudinal imaging and direct measures of fluid flow are needed to understand what drives these changes.

Source: Fernandes F, Dey A, Ma A, et al., Choroid plexus volume in pathology-confirmed Alzheimer's disease, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100648 (CC BY 4.0)

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Special care units for people with dementia who have agitation and other behavioral symptoms offer a home-like setting with specialized staff. But are they worth the money? The European RECage study followed 508 people for three years across Italy, Switzerland, Germany, Norway, France, and Greece, comparing those cared for in these units with those who were not. Over three years, the special care unit group had slightly fewer quality-adjusted life years (about 0.13 fewer) and roughly €25,000 higher total costs, so the units were likely not cost-effective in this analysis. Because the study was observational and the results are uncertain, the authors say neither widespread rollout nor cutting these units can be recommended yet, and they call for a randomized study stratified by region.

Source: Handels R, Michalowsky B, Mendes A, et al., Cost-effectiveness of the special care unit for persons with dementia, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100647 (CC BY 4.0)

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Machine learning can forecast how fast thinking skills will slip — but how well do those models work on a new group of patients? Researchers in Zurich trained models on ADNI (1,237 people) and OASIS-3 (662 people) to predict yearly change in CDR-SOB and MMSE scores. Adding structural MRI to clinical and demographic data improved predictions inside each dataset (R² up to about 0.41–0.42 for CDR-SOB). When the same models were tested on the other cohort, performance dropped (R² roughly 0.18–0.35). Slimming the models to only the top predictors did about as well externally, which points to redundant features rather than a free lunch. The paper argues that measuring this generalizability gap is essential before trusting these tools for individual planning.

Source: Hüppi RM, Langer N, Vieira BH, Quantifying generalization error in machine learning prediction of cognitive decline, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100646 (CC BY 4.0)

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Can the shape of your brain's memory center reveal risk that amyloid tests miss? Researchers at UC Irvine studied MRI scans and up to 10 years of follow-up in 1,142 dementia-free older adults from the Alzheimer's Disease Neuroimaging Initiative. Smaller overall hippocampal volume tracked with worse thinking and faster decline in every area tested. But a bigger size difference between the left and right hippocampus was tied specifically to memory decline, and it predicted progression to dementia only in people without detectable amyloid. The authors suggest hippocampal asymmetry may flag brain changes that go beyond classic Alzheimer's pathology.

Source: Ghanbarian E, et al., Hippocampal asymmetry captures non-amyloid-related risk of memory decline and clinical progression, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100638 (CC BY 4.0)

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Could a routine eye exam one day flag Alzheimer's disease? Because the retina is an extension of the brain, this study used a genetic method called Mendelian randomization, drawing on large genetic datasets and more than 52,000 UK Biobank participants, to sort out which eye changes Alzheimer's actually causes. Genetic risk for Alzheimer's was linked to more twisted small arteries in the retina, with weaker hints of thinning in the inner retinal layers. An apparent link between optic disc size and Alzheimer's was probably explained by refractive error. The authors say more work is needed before eye screening for dementia is ready for the clinic.

Source: Kiser H, et al., Can we identify people with Alzheimer's disease from examination of the eye? A bidirectional Mendelian randomization (MR) study, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100635 (CC BY 4.0)

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Enlarged perivascular spaces, the fluid-filled channels around small blood vessels in the brain, show up on routine MRI. This study of 307 people with cognitive impairment from a Seoul dementia cohort asked whether amyloid and blood vessel disease leave different patterns of these spaces.

Vascular burden was linked to more enlarged spaces deep in the basal ganglia, regardless of amyloid. Amyloid and vascular disease were each linked to more spaces in the parietal, temporal, and occipital white matter, with no extra increase when both were present. The spatial pattern may help hint at which pathologies are driving cognitive impairment.

This episode is an AI deep-dive overview of the open-access paper. It sticks to what the study reports.

Source: Kim W, et al., Distinct spatial patterns of perivascular spaces enlargement for multiple and co-existing pathologies of cognitive impairment, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100631 (CC BY 4.0)

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

How do clinicians tell mild dementia from moderate dementia? This study tested the Functional Activities Questionnaire, an informant-based checklist of everyday tasks, in more than 34,000 people from the US NACC database and confirmed the results in the ADNI and FTLDNI cohorts. A score of 18 or higher caught 96% of moderate dementia cases, while a cut-off of 23 traded a little sensitivity for higher specificity. Older age and lower cognitive scores made misclassification more likely.

Source: Ersözlü E, et al., Drawing a line: Differentiating mild from moderate dementia using the functional activities questionnaire, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100630 (CC BY 4.0)

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Using amyloid and tau PET scans from two US cohorts, ADNI and the Harvard Aging Brain Study, researchers estimated how long it takes to go from amyloid positivity to tau positivity. That interval varied widely and was shorter in APOE4 carriers, women, and people who became amyloid positive at older ages. A shorter amyloid-to-tau interval predicted earlier symptom onset, pointing to a narrower window for early detection in these groups.

Source: Milà-Alomà M, et al., The time interval from amyloid to tau PET positivity varies by age, sex and APOE-ε4 status, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100622 (CC BY 4.0)

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

A gut bacterial compound called imidazole propionate (ImP) is linked to Alzheimer's-related brain changes and faster cognitive decline in a large Wisconsin cohort, with mouse and cell studies pointing to barrier and tau pathways.

Researchers measured blood ImP in nearly 1,200 mostly cognitively unimpaired adults, connected ImP-producing gut bacteria to disease markers, and found a genetic signal tied to both ImP levels and Alzheimer's risk. In mice, chronic ImP worsened Alzheimer-like pathology.

This episode is an AI deep-dive overview of the open-access Nature Communications paper. It sticks to what the study reports.

Source: Vemuganti V et al., Gut bacterial metabolite imidazole propionate potentiates Alzheimer's disease pathology. Nat Commun. 2026. doi:10.1038/s41467-026-74744-z (CC BY 4.0)

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

A Mendelian randomization study of plasma proteins, structural MRI measures, and Alzheimer's disease risk found 12 neuroimaging metrics and 1,633 proteins with causal ties to AD. Brain imaging also mediated about 67% of the link between the immune-related protein PTPRC and Alzheimer's risk across the disease course.

Source: Xu X, et al., Bidirectional causal relationships between plasma proteins, neuroimaging metrics and risk of Alzheimer's disease, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100619 (CC BY 4.0)

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

A letter responds to a large review of public dementia risk awareness, arguing that recognizing a risk factor is not the same as knowing what to do about it. The authors urge surveys to measure actionable knowledge, whether risks are personal habits or policy problems, and to separate fear and stigma from true risk perception.

Source: Xie Z, Su J, Liao T, Beyond recognition: Refining the assessment of public knowledge and risk perception in dementia prevention, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100602 (CC BY 4.0)

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Should doctors check brain health the way they check blood pressure? In this editorial, neurologist Gregory Cooper looks at the Brain Health Vital Signs project, which scores patients on 15 lifestyle risk factors for dementia. He explains how the FINGER, US POINTER, and LatAm-FINGERS trials showed that exercise, diet, mental challenge, social connection, and heart health can protect thinking skills, and why clinics now need practical ways to help patients with memory problems follow that advice.

Source: Cooper G, Is it time to make brain health a vital sign?, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100654 (CC BY 4.0)

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Does what you eat shape your risk of Alzheimer's disease, and does the answer change between Eastern and Western diets? This episode digs into a 2026 review in the Journal of Prevention of Alzheimer's Disease that compares dietary patterns across East and West, including the Mediterranean and MIND diets and traditional Asian eating patterns, and what the evidence says about future diet-based prevention strategies for dementia and brain health.

Source: Jiang et al., "Dietary patterns and Alzheimer's disease: East-west perspectives and future intervention strategies," J Prev Alzheimers Dis. 2026. https://doi.org/10.1016/j.tjpad.2026.100636

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

People with atrial fibrillation (AFib), a common irregular heart rhythm, face a higher risk of developing dementia. This study followed 91,795 UK Biobank participants who wore activity trackers. It found that people with AFib who got at least 150 minutes a week of moderate-to-vigorous activity had a lower AFib-related dementia risk. Interestingly, the activity people reported themselves only loosely matched what the trackers measured, and self-reported activity wasn't linked to lower dementia risk. The findings suggest that staying active may help protect brain health in people with AFib, though longer studies are needed to confirm this.

Source: Le Li, Mengtong Xu, Lingmin Wu, et al., Effect of accelerometer-measured physical activity on the association between atrial fibrillation and risk of dementia, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100603 (CC BY 4.0)

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

You know that moment when you open the refrigerator and forget what you came for, or you recognize an actor’s face but their name is gone? Most of us laugh it off, but the fear behind it is real: what if it’s not stress or sleep, but the earliest sign of Alzheimer’s disease?

We break down a landmark 2026 study that asks a surprisingly uncomfortable question: who is the more reliable narrator of your cognitive health, you or the person closest to you? Using the Everyday Cognition (ECog) questionnaire across large longitudinal cohorts, researchers compare self-reports with “study partner” reports from spouses and adult children, then link both to hard biology like amyloid beta and tau. Along the way we explain why quick screening tools like the MMSE can miss subtle declines in planning, language, navigation, and multitasking, and why a single baseline snapshot can be misleading when Alzheimer’s pathology can build silently for years.

The most important twist is about insight. As Alzheimer’s progresses, many people begin to lose accurate self-awareness due to anosognosia, a neurological inability to perceive impairment that is not simple denial. That’s why the partner’s year-over-year observations can become the loudest early alarm, and why a one-year increase in partner-rated ECog can signal sharply higher near-term risk when amyloid is present. We also zoom out to the big implication: what happens to early detection for people who live alone, and could AI, wearables, or smart homes someday act as a “digital study partner”?

If this made you rethink memory concerns and caregiver observations, subscribe, share this with someone supporting an aging loved one, and leave a review with the biggest question you’re still sitting with.

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

In the European Union, the Alzheimer's drug donanemab is approved for a narrower group of people with early symptomatic Alzheimer's disease. They must carry no copies or one copy of the APOE ε4 gene variant, and they can't have certain signs of brain bleeding, uncontrolled high blood pressure, or be taking blood thinners. This analysis of the TRAILBLAZER-ALZ 2 trial looked only at participants who would meet those EU criteria. In that group, donanemab slowed disease progression compared with placebo, and the benefit grew over 154 weeks of follow-up. The safety profile was described as manageable, though brain swelling (ARIA-E) and infusion reactions still happened in some patients. It shows how the drug performs in the patients European doctors can actually prescribe it for.

Source: Frank Jessen, Grazia Dell'Agnello, Jennifer A. Zimmer, et al., Efficacy and safety of donanemab in the European eligible population: TRAILBLAZER-ALZ 2 post-hoc analyses, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100605 (CC BY 4.0)

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Alzheimer’s has been treated like a neuron problem for decades, but what if the real lever sits in the brain’s support system, quietly failing long before symptoms show up? We dig into a 2026 Journal of Prevention of Alzheimer’s Disease paper that uses a massive transcriptomic dragnet across multiple human datasets to spotlight one surprising hub: CD44, a receptor best known outside the brain, now showing up as a major signal across vulnerable Alzheimer’s regions.

We walk through why amyloid plaque clearing therapies can slow decline yet still come with modest benefit and serious tradeoffs like ARIA, frequent infusions, and intensive monitoring. Then we follow the evidence trail: region-by-region gene expression analysis, network hub logic, convergent functional genomic ranking, and the clinical “timeline paradox” where CD44 spikes in asymptomatic Alzheimer’s but does not neatly track with later cognitive severity. That pattern pushes us to treat CD44 as an early priming event, not a late-stage scar.

The biggest shift comes from single-nucleus RNA sequencing. CD44 is not coming from dying neurons. It is concentrated in astrocytes, particularly a neurotoxic reactive subpopulation tied to impaired autophagy, the brain’s protein waste recycling system. Using cell-to-cell communication modeling, the paper implicates microglial osteopontin (SPP1) signaling into astrocyte CD44, potentially jamming intracellular transport and stalling autophagic “garbage trucks.” We also cover the Petri-dish validation where CD44 knockdown restores autophagic flux markers and CD44 overexpression makes them worse.

If you care about Alzheimer’s disease research, astrocytes, microglia, autophagy, and next-generation therapeutic targets beyond amyloid, this is the map. Subscribe, share this with a friend who follows neuroscience, and leave a review with your take: should the next wave of trials prioritize restoring brain cleanup over clearing plaques?

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Your shoulders creep toward your ears during a brutal month. Your chest tightens during panic. Your body feels heavy during depression. We usually call those downstream symptoms, but the research we’re unpacking argues for something far more disruptive: fascia may help generate the very emotional states we blame on the brain alone.

We walk through a major 2026 review that reframes fascia as a continuous, body-wide sensory network rather than inert “wrapping paper.” From superficial fascia under the skin to deep fascia that transmits force, visceral fascia that lets organs glide, and parietal fascia that shapes the felt boundaries of the body, the anatomy sets the stage for the mental health link. Then we zoom into neurology: roughly 250 million nerve endings feeding interoception and proprioception, creating the quiet background signal that can register as safety, grounding, and mood.

From there, we trace the mechanism from chronic stress, trauma, and insomnia to sympathetic overactivity, ischemia, inflammation, TGF beta 1 signaling, and fibroblasts shifting into contractile myofibroblasts. Add hyaluronic acid densification and you get a stiff, sticky matrix that can distort afferent input into “interoceptive noise.” We connect that noise to anxiety, depression, altered pain perception, and findings from TMS studies that suggest reduced cortical inhibition. Finally, we get practical: mechanotransduction through sustained stretching, myofascial release, yoga, and somatic meditation, plus the role of diaphragmatic breathing and the vagus nerve in restoring parasympathetic balance.

If you’ve ever felt like your body won’t let your mind calm down, this deep dive is for you. Subscribe, share this with someone who lives in tension, and leave a review with one question you want answered next.

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

What if the clearest signal about your brain’s future isn’t hidden inside an MRI, but floating in your blood right now? We dig into Neurofilament Light Chain (NFL), a nervous system biomarker that behaves like a smoke alarm for ongoing nerve damage and could help shift brain health from reactive to proactive.

We anchor the story in a remarkable study of 495 Japanese centenarians followed for up to 17 years. Researchers measured amyloid beta, phosphorylated tau, and NFL, and NFL came out on top for predicting cognitive function and mortality risk. That result forces a bigger rethink: clearing plaques may not be the same thing as slowing structural wear and tear across the brain and spinal cord, which helps explain why some Alzheimer’s drugs show modest cognitive benefits even when they hit their biological target.

From there, we break down the actual biology in plain language. Axons are long “cables,” NFL is part of their internal scaffolding, and when those cables degrade, NFL leaks into cerebrospinal fluid and then into the bloodstream. New ultrasensitive blood assays like Quanterix Simoa make it measurable without a spinal tap, opening the door to cheaper, repeatable tracking that can respond in weeks, not years.

We also get practical about how to use an NFL blood test wisely: why the trend line matters more than a single number, why you should avoid testing right after intense exercise, how obesity can falsely “lower” NFL via dilution, and which health factors tend to push NFL higher (sleep apnea, hypertension, diabetes, kidney disease, inflammation). We close with where this is heading next: tiered screening and “triggered prevention,” plus the open questions about baselines across different populations.

If you found this useful, subscribe, share it with someone who cares about brain health, and leave a review. What would you want to learn from your own NFL trajectory?

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

You’ve heard the standard dementia prevention script: eat well, sleep more, do the puzzles, and hope for good genes. Then a result lands that doesn’t fit the script at all, a routine shingles vaccine associated with a 33% lower risk of dementia in a real-world study of 1.5 million Medicare patients. We dig into what that finding does and does not mean, why it’s so hard to dismiss, and how it compares to the modest wins medicine has chased for decades with expensive Alzheimer’s drugs. 

From there, we follow the science into the infection hypothesis and the surprisingly consistent epidemiology linking herpes viruses to cognitive decline. We talk HSV1 in the brain, the APOE4 connection, and the registry data showing dementia risk rising after severe herpes infections and falling with antiviral treatment. Then we flip the usual amyloid story on its head: amyloid plaques may act like an ancient antimicrobial defense, trapping pathogens like a biological cage, helpful in the short term and harmful when chronic reactivation keeps triggering more buildup. 

We also tackle the shingles puzzle with bioengineered brain tissue research suggesting shingles-related inflammation can “wake up” dormant HSV1 and spark Alzheimer’s-like changes. We zoom out to other viral evidence like EBV and MS, then bring it home with COVID-19 biomarker and imaging findings while keeping the risk in perspective. Finally, we translate all of this into action: shingles and flu vaccine data, what’s unsettled about COVID vaccination studies, and why an adjuvant called AS01 might be a key clue for immune-driven plaque cleanup. If this reshapes how you think about brain health, subscribe, share this with someone caring for aging parents, and leave a review with your biggest question about vaccines and dementia prevention.

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Alzheimer’s has been sold to all of us as a neuron story: plaques, tangles, and brain cells fading away. But the data we walk through here points to a more unsettling possibility that the real tipping point is structural. When the brain’s blood vessels fail, memory can fall apart even faster, and what looks like “classic Alzheimer’s dementia” may actually be a vascular collapse hiding in plain sight.

We unpack a large autopsy analysis from the NACC database and use it to zoom in on cerebral amyloid angiopathy (CAA), where amyloid beta doesn’t just sit in brain tissue but builds up inside vessel walls. That shift changes everything. We explain the amyloid overflow hypothesis, how perivascular drainage pathways get overwhelmed with age, and why brittle arteries can set off microinfarcts that quietly sever brain networks over years. We also dig into a key double dissociation: CAA drives cortical microinfarcts, while hypertension-related arteriolosclerosis drives deep subcortical injury, meaning blood pressure control is essential but not the whole answer for Alzheimer’s-related vascular damage.

Then we go one layer deeper into genetics and the neurovascular unit. APOE ε4 shows up not only as an amyloid risk factor, but as a threat to blood-brain barrier integrity, letting proteins like fibrinogen leak into the brain and ignite microglia-driven inflammation. Finally, we connect these mechanisms to the new era of anti-amyloid monoclonal antibodies, ARIA risk, and why clearing plaques without accounting for “the state of the pipes” may limit real-world cognitive benefit.

If this reframes how you think about Alzheimer’s disease, vascular dementia, CAA, microinfarcts, and precision medicine, subscribe, share this with a friend, and leave a review. What do you think matters more for preventing dementia: removing amyloid or protecting brain blood vessels?

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Fish oil has a near-halo status in nutrition culture: a simple, golden capsule that promises better memory, sharper thinking, and protection from cognitive decline. But a landmark longitudinal analysis using ADNI data and published in the Journal of Prevention of Alzheimer’s Disease forces a rethink, suggesting omega-3 supplement use in older adults may be linked to accelerated decline on major cognitive and functional scales. That tension between “common wisdom” and long-term human data is where we start, and we don’t let easy explanations off the hook. 

We walk through how the researchers compare supplement users and non-users over a five-year follow-up, why healthy user bias can mislead almost every supplement story, and how propensity score matching creates closer “statistical twins” across age, diagnosis, and APOE ε4 risk. We also tackle the most obvious defense, reverse causality, by looking at pre-supplement trajectories and the timing of decline. Then we quantify what “faster decline” means across MMSE, ADAS-Cog 13, and CDR-SB, translating abstract percentages into real-world loss of memory and independence. 

The biggest twist: the decline doesn’t seem to ride on the usual Alzheimer’s markers. Amyloid plaques, tau tangles, and gray matter loss don’t budge. Instead, FDG-PET points to reduced glucose metabolism, an “electrical brownout” where synapses lose energy even when the structure looks intact. From there we explore a plausible mechanism centered on DHA instability, lipid peroxidation, mitochondrial dysfunction, and a self-reinforcing oxidative cycle, plus why supplement quality and oxidation risk may separate “rancid reality” from purified trial products. We close with nuance, including the U-shaped dose-dependent paradox, and a bigger question about oxidizable fats in the modern diet. 
Subscribe for more deep dives, share this with a friend who takes fish oil, and leave a review with your take: are supplements helping your brain, or just sounding like they should?

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

What if the biggest lever for preventing dementia isn’t hidden in your DNA, but sitting in your calendar, your sleep, your diet, and even your hearing? We dig into a 2026 German study published in the Journal of Prevention of Alzheimer’s Disease that argues up to 45% of dementia risk is modifiable and then shows what “modifiable” actually looks like when you measure it person by person. 

We walk through how Brain Health Services flip the old model of waiting for symptoms into proactive brain health screening for people who feel fine today. The surprise is how many “worried well” participants still carried meaningful, fixable vulnerabilities: obesity, low Mediterranean diet adherence, poor subjective sleep quality, chronic stress, and hearing impairment. Using principal component analysis, the study groups real-world dementia risk factors into six practical clusters: psychosocial load, blood pressure, physical condition, hearing, lifestyle, and substance use. 

Then we connect those clusters to hard biology. We explain why hearing loss can raise cognitive load and push social isolation, why physical condition correlates with blood biomarkers like neurofilament light chain (NFL) and GFAP, and what those markers suggest about neurodegeneration and neuroinflammation. We also tackle the APOE4 question and the empowering takeaway that genetic predisposition does not erase the impact of fundamentals like sleep, exercise, diet, and stress skills. 

The most hopeful part: a single two-hour, hyperpersonalized assessment plus tailored counseling leads to reported lifestyle improvements for over 60% of respondents at six months. Listen, share this with someone who’s worried about cognitive decline, and leave us a review. Which one cluster would you “audit” first: sleep and stress, blood pressure, fitness, hearing, lifestyle, or substance use?

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Alzheimer’s doesn’t wait for a diagnosis to begin. The brain changes can start quietly for years, even a decade, while someone looks totally fine, passes cognitive tests, drives, works, and pays the same routine healthcare bills as their peers. That raises a tough question with massive public health stakes: if the disease is already active, when does it start costing Medicare real money?

We dig into a 2026 Journal of Prevention of Alzheimer’s Disease study that finally connects two missing halves of the puzzle: precise clinical trial data from cognitively normal adults with confirmed amyloid pathology, and real-world Medicare claims that record hospital stays, ER visits, home health care, and actual dollars spent. The surprising baseline finding is a true economic paradox: elevated amyloid alone does not meaningfully raise healthcare utilization or Medicare payments. The spending surge arrives later, when cognitive decline becomes disruptive enough to show up in claims and when frailty ramps up.

The most important takeaway is what drives the spike. It is not primarily dementia-specific treatment. Costs jump because slipping executive function makes everyday chronic disease management fall apart, turning “cheap” conditions like hypertension or diabetes into emergencies like falls, injuries, surgeries, and long recovery stays. We also talk about the detection gap between sensitive research tools and rushed primary care, why cognitive reserve may delay the tipping point for highly educated cohorts, and the provocative next frontier: if blood tests like p-tau217 make preclinical Alzheimer’s visible to everyone, does knowledge alone change behavior and spending before symptoms begin?

If this changed how you think about Alzheimer’s prevention, share it with someone who needs it, and subscribe, rate, and review so more people can find the show.

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

A clean diagnosis feels like an X-ray: obvious problem, obvious fix. Alzheimer’s disease is the opposite, and the arrival of disease-modifying anti-amyloid therapies like lecanemab and donanemab makes that gap impossible to ignore. We dig into why real-world patients do not look like “pristine” clinical trial participants, and why a simple amyloid positive label can hide wildly different biology, risks, and likely outcomes.

We explore what happens when amyloid burden is patchy or borderline, how centiloid scores and CSF biomarkers (especially the amyloid beta 42 to 40 ratio) create a probabilistic gray zone, and why cognitive decline often reflects more than plaques alone. Cerebrovascular disease and white matter injury can team up with modest amyloid to push a brain over the edge, which changes what “treating the cause” even means.

Then we follow the fire inward to tau. Tau tangles disrupt neurons from the inside, and tau PET with Braak staging can reveal severe pathology even when someone still functions well, thanks to cognitive reserve. From there, we zoom out to the ATNIVS framework: Amyloid, Tau, Neurodegeneration, Inflammation, Vascular pathology, and Synuclein. We connect blood biomarkers like plasma NFL and GFAP to active neurodegeneration and neuroinflammation, and we explain why ARIA (amyloid-related imaging abnormalities) risk rises when fragile vessels, inflammation, and cerebral amyloid angiopathy collide with plaque-clearing antibodies.

Finally, we cover a provocative twist: seed amplification assays detecting hidden alpha-synuclein in a meaningful share of patients diagnosed with Alzheimer’s, pointing to copathology that can change prognosis and potentially mask drug benefit. If you care about Alzheimer’s biomarkers, precision neurology, and the future of combination therapies, listen through to the end, then subscribe, share the episode, and leave a review with your biggest takeaway.

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Your brain is an energy hog running on an ATP battery that lasts only seconds, and that one fact changes how you should think about “brain supplements.” We dig into why creatine is more than a weightlifting staple, how phosphocreatine works like a built-in power bank, and why the blood brain barrier makes brain saturation slow, picky, and easy to study the wrong way. If you’ve ever tried to boost focus and felt buried under wellness noise, this is the signal. 

We walk through the groups most likely to feel a real cognitive effect: vegans and vegetarians with lower dietary creatine exposure, older adults facing slower creatine synthesis and mitochondrial decline, and anyone under acute metabolic stress. The sleep deprivation trials are especially wild, showing that a high single dose during severe sleep loss can preserve ATP and reduce the cognitive crash, while still not replacing the deeper restorative work that sleep does. 

We also get honest about the clinical landscape: a small Alzheimer’s pilot shows a measurable brain-creatine increase and improved scores, while massive Parkinson’s and Huntington’s trials show no slowing of progression, pointing to the difference between metabolic failure and structural damage. Then we bring it back to practical guidance: why “creatinine” on a standard blood panel can mislead, why serum levels do not equal brain uptake, what dosing looks like in studies, how to pick creatine monohydrate with third-party testing, and which internet myths don’t hold up. If this helped you, subscribe, share it with a friend who’s running on fumes, and leave a review with your biggest creatine question.

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Sleep turns on a hidden plumbing system that pressure-washes the brain, clearing toxic waste that builds up during wakefulness. We connect brand-new human imaging with practical sleep habits so you can protect deep sleep, memory, and long-term cognitive health. 
• why the brain accumulates metabolic waste while awake 
• how the glymphatic system works and why science missed it for decades 
• the mouse discovery in 2012 and the 2024 human proof using gadolinium plus specialized MRI 
• perivascular spaces as the brain’s fluid highways 
• astrocytes, AQP4 water channels, and why deep sleep expands interstitial space 
• vasomotion as the mechanical pump and how slow wave brain activity controls it 
• amyloid beta and tau clearance plus the vicious cycle linking poor sleep and neurodegeneration 
• epidemiology on sleep duration, dementia risk, and why the curve is U-shaped 
• the medication paradox with sedatives like Ambien and why unconsciousness is not the same as restorative sleep 
• lifestyle levers: exercise, blood pressure control, side sleeping, alcohol timing, meal timing, and light exposure 
Take care of your brain, manage your blood pressure, and get a really good sideline night of sleep. 

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

A probiotic is supposed to help you recover after antibiotics. But what if the wrong probiotic acts like an invasive weed, moves into the empty real estate in your gut, and blocks your native microbiome from growing back? We unpack the science behind that unsettling possibility and use a comprehensive medical review by Dr. Kristen Glorioso to separate real microbiome research from gut health marketing that promises weight loss, brain fog cures, and “perfect” stool test scores.

We walk through why the gut microbiome is an ecosystem, not an arcade game. Some of the most important organisms are strict anaerobes that cannot survive oxygen, so they are not something you can reliably buy in a capsule. We explore why microbes like Akkermansia muciniphila and Prevotella copri can be helpful in one context and harmful in another, and how competitive nutrient exclusion explains why diversity can be protective. Then we zoom out to the “for whom” problem: genetics, ancestry, and age can shift what a healthy baseline looks like, including research tying APOE4 to lower butyrate producing bacteria and downstream effects on inflammation and the blood brain barrier.

From there, we get practical. We break down the post antibiotic study where a multi strain probiotic delayed recovery versus watchful waiting, why autologous fecal microbiota transplant can restore an ecosystem fast yet remains hard to implement, and what consistently works for most people: plant diversity like the 30 plants per week approach, whole foods that deliver fiber to the colon, live culture fermented foods, and aerobic exercise. We also clarify microbiome testing options, from 16S sequencing to shotgun metagenomics and metatranscriptomics, and how to use results to track change rather than chase a generic reference range.

If you want a smarter, calmer way to think about gut health, hit play, then subscribe, share this with a friend who loves probiotics, and leave a review with your biggest takeaway or question.

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

A heart that ticks like a perfect metronome sounds reassuring, but it can be a warning sign. We dig into heart rate variability (HRV) and why the healthiest hearts show constant micro-adjustments between beats, reflecting a nervous system that can hit the gas when it needs to and slam the brakes when it’s time to recover. If you’ve ever stared at your Apple Watch, Oura Ring, Garmin, or Whoop score and wondered what it actually means, we translate the physiology into plain English. 

We walk through the autonomic nervous system tug-of-war between the sympathetic “fight or flight” response and the parasympathetic vagus nerve, then connect HRV to something bigger than fitness: inflammation control. The vagus nerve doesn’t just calm you down; it can signal immune cells to stop releasing inflammatory messengers like TNF alpha and IL-6. When that brake weakens, chronic low-grade inflammation can rise, and the downstream links to brain health get hard to ignore, from the Parkinson’s gut-brain hypothesis to cholinergic vulnerabilities that show up early in Alzheimer’s disease. 

Then we get practical and skeptical. We cover RMSSD, why optical wrist sensors differ from ECG, why comparing scores with friends is pointless, and why a sustained drop from your personal baseline matters more than daily noise. We also add a missing metric that changes the risk picture: blood pressure variability. Finally, we lay out an evidence-based playbook for improving HRV without falling for biohacking hype, including zone 2 cardio, slow breathing at five to seven breaths per minute, protecting sleep, cutting evening alcohol, and taking stress and loneliness seriously. If this helped, subscribe, share it with a friend who tracks HRV, and leave a review with your biggest takeaway.

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Some brains carry severe Alzheimer’s pathology while staying cognitively normal, and that paradox forces us to rethink what “prevention” can honestly mean. We map the data behind cognitive reserve, the 2024 Lancet risk factors, the U.S. POINTER lifestyle trial, and the promise and limits of anti-amyloid drugs. 
• primary prevention versus secondary prevention definitions 
• compression of morbidity as the practical goal 
• cognitive reserve as neural “side streets” 
• what the Lancet 2024 45% estimate really measures 
• why education strengthens cognitive resilience early in life 
• hearing loss mechanisms including cognitive load and atrophy 
• LDL cholesterol damage to the blood-brain barrier and inflammation 
• late-life risks like isolation, smoking, vision loss, air pollution 
• U.S. POINTER trial design and what the structured program requires 
• why small effect sizes can still matter at scale 
• midlife hypertension timing and reverse causation pitfalls 
• type 2 diabetes and brain insulin resistance “type 3 diabetes” framing 
• anti-amyloid monoclonal antibodies benefits and ARIA risks 
• a three-tier framework: strong consensus, emerging science, failed hypotheses 
• why passive supplements beat active habits in real-world behavior 
go check your blood pressure. 

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

We stop obsessing over wrinkles and start looking at the real “cellular battery” that powers aging: NAD+. We weigh the hype against NIH workshop science, clinical trial signals, and the blunt reminder that exercise can raise NAD+ to youthful levels without a biohacker budget. 
• NAD+ as a coenzyme that converts food into ATP 
• NAD+ role in DNA repair enzymes and cellular maintenance 
• sirtuins debate and why top researchers disagree 
• Sinclair’s NMN mouse data and frailty clock claims 
• Brenner’s evolutionary argument for stress response biology 
• NAD World signaling between adipose tissue and hypothalamus 
• microbiome trade that helps the host synthesize NAD+ 
• why oral NAD+ fails and precursors like NR and NMN dominate 
• first-pass metabolism limits supplements and drives IV therapy demand 
• NR vs NMN head-to-head data on blood NAD+ increases 
• brain NAD+ challenges and why consistent dosing matters 
• clinical trial mechanisms for blood pressure, insulin sensitivity, and mitophagy 
• the exercise finding that reframes the whole longevity narrative 
• aging as a communication breakdown across organs 

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

We trace how autophagy keeps us alive by turning cells into disciplined self-recyclers when nutrients drop, then map the real control switches that wellness culture often gets wrong. We follow the story from lysosomes and yeast genetics to MTORC1, spermidine, and why the healthiest strategy is balance between building and cleaning. 
• what autophagy is and why “self-eating” is survival, not a gimmick 
• how lysosomes and autophagosomes work as an incinerator and garbage trucks 
• how Ohsumi’s yeast experiments revealed ATG genes and proved conservation across species 
• how MTORC1 senses nutrients and blocks autophagy through phosphorylation and TFEB control 
• why constant snacking can keep MTORC1 stuck on and slow cellular cleanup 
• how fasting triggers spermidine and why spermidine is required for autophagy induction 
• how EIF5A hypusination prevents ribosome stalling on autophagy-related proteins 
• why impaired autophagy links to protein aggregates, mitochondrial damage, inflammation, and metabolic disease 
• the neonatal mouse evidence showing failure to trigger autophagy can be fatal 
• Cleveland Clinic cautions on extreme fasting and who should avoid it 
• where research is heading with caloric restriction mimetics such as spermidine and resveratrol pathways 

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

We follow the science that links deep sleep, circadian timing, and brain energy to how fast we age. We connect glymphatic waste clearance, the SCN master clock, melatonin biology, and meal timing to Alzheimer’s risk, memory function, and longevity.
• the glymphatic system as a deep sleep waste-clearance mechanism for amyloid beta and tau
• how cerebrospinal fluid moves through perivascular spaces and drains to lymph nodes
• why aquaporin-4 channels act like valves and how aging makes the plumbing inefficient
• 40 hertz gamma entrainment as a non-invasive attempt to boost clearance plus limits and unknowns
• why pharmacological “forcing” of clearance risks systemic side effects and is not a simple fix
• the SCN as the master circadian clock that uses light to time cortisol, sex hormones, and thyroid output
• circadian syndrome as a pathway to mitochondrial dysfunction and oxidative stress in neurons
• the hamster SCN transplant studies that restore rhythms and extend lifespan
• melatonin as a whole-body timing signal that influences epigenetics via SIRT1 and supports healthy autophagy
• why sleep deprivation triggers synaptic scaling problems and a chemical lockdown of memory circuits
• clock-aligned eating and time-restricted feeding as a way to resynchronize peripheral clocks
• the BMAL1 paradox showing caloric restriction can fail or harm when clock machinery is broken

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

We follow the real mechanics behind the 5,000-year lifespan headline and land on what telomeres actually do inside your cells. We trace the Goldilocks tradeoff where telomeres protect you from cancer while also setting you up for organ failure if they run too short, then weigh what lifestyle science can change without reckless biohacking. 
• telomeres as non-coding DNA buffers that protect chromosomes 
• the end replication problem as a built-in shortening clock 
• shelterin protection and the senescence alarm 
• telomerase discovery and why it matters clinically 
• short telomere syndromes leading to marrow failure in kids 
• the short telomere paradox in adult lung fibrosis 
• SASP inflammation driving scarring through fibroblasts 
• why telomere shortening can suppress solid tumors 
• immune surveillance failure explaining opportunistic skin cancers 
• the long telomere paradox as a cancer risk factor 
• somatic reversion as natural genetic “rescue” in marrow 
• the Ornish and Blackburn lifestyle trial and its dose response 
• oxidative stress and inflammation as the chemical scissors 
• caloric restriction benefits versus human costs 
• growth hormone as cosmetic youth with biological risk 
• ethical stakes from distributive justice to gerontocracy 
Keep digging into the literature, to keep questioning the hype, and we'll catch you on the next deep dive. 

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

We trace how cellular senescence turns damaged cells into “zombies” that stay alive, stop dividing, and poison nearby tissue with the SASP inflammatory cocktail. We weigh what the best human trials actually show about senolytics and why the next wave of precision therapies may matter more than today’s supplement hype.
• cellular senescence as an active stress state, not “cells getting tired”
• the Hayflick limit, telomeres, and why senescence starts as tumor suppression
• SASP as the driver of tissue damage, bystander effects, and inflammaging
• antagonistic pleiotropy and why SASP can help early-life healing
• immunosenescence as the reason senescent cells accumulate with age
• senolytics and survival pathways that keep senescent cells alive
• dasatinib plus quercetin and the logic of hit-and-run dosing
• Mayo Clinic data suggesting benefits depend on baseline senescent burden
• fisetin osteoarthritis trial and how bioavailability can erase lab promise
• senomorphics that silence SASP when cells are “load bearing”
• precision approaches like suicide gene therapy and senescence-targeted CAR-T
• the “psychoage” question of what longer healthspan does to human urgency

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

We follow the real mechanics of aging down to mitochondrial quality control and the surprising idea that staying functional depends on controlled breakdown, not preservation. We connect exercise, fasting, and emerging longevity compounds to the same core requirement: mitochondria must keep reshaping, recycling, and rebuilding. 
• mitochondria as regulators of immunity, apoptosis, and systemic aging 
• ROS damage to membranes and mtDNA as the “rust” of metabolism 
• quality control escalation from UPRmt to MDVs to mitophagy 
• fission and fusion as non-negotiable mitochondrial dynamics 
• DRP1 fission to quarantine damage and enable mitophagy 
• fusion proteins restoring a stronger interconnected network 
• exercise-driven fragmentation followed by recovery-driven fusion 
• AMPK sensing AMP:ATP to trigger ULK1 cleanup and PGC-1α biogenesis 
• sirtuins, NAD+ decline with age, and the PINK1-Parkin pathway 
• metformin as a partial AMPK-linked mimic with real limits 
• caloric restriction data showing more mitochondria and greater efficiency 
• nitric oxide as a biogenesis signal with a dose-dependent tradeoff 
• NMN and NR as NAD+ precursors to fuel mitochondrial repair pathways 
• SS-31 binding cardiolipin to protect inner membrane structure 
• spermidine, urolithin A, and tomatidine as diet-linked mitophagy levers 
• stem-cell mitochondrial transfer via vesicles and tunneling nanotubes 
• the closing question of whether aging is a community failure 

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

We follow rapamycin from a soil sample on Easter Island to the center of longevity science, then break down how mTOR decides between growth and repair. We also confront the “friendly fire” problem that shows up with chronic dosing and explain why current trials focus on precision pulsing and measurable biomarkers. 
• the 1975 discovery story and why rapamycin was shelved then revived for organ transplantation 
• how TOR genes led to mTOR and why phosphorylation changes protein shape and function 
• mTOR as a nutrient and energy sensor integrating leucine, arginine, ATP, oxygen, and insulin 
• why nonstop mTORC1 activity links to senescence, SASP inflammation, and age-related decline 
• how rapamycin inhibits mTORC1 to unlock autophagy and act as a calorie restriction mimetic 
• what mTORC2 does for cell survival and why losing it can wreck glucose control 
• animal evidence across species including late-life mouse benefits and sex differences 
• why companion dog trials matter and what improved heart function suggests 
• the Fang study logic behind insulin resistance with chronic exposure and later adaptation 
• how human trials use intermittent dosing plus epigenetic clocks, cytokines, metabolic labs, and functional tests 
Keep questioning the world around you. Keep an eye on those clinical trials, and don’t forget to let yourselves take out the trash. 

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!